Free Trial
→ Think NVDA’s run was epic? You ain’t seen nothin’ yet (From Timothy Sykes) (Ad) Buy IPHYF Stock  Free IPHYF Stock Alerts

Innate Pharma (IPHYF) SEC Filings & 10K Form

Innate Pharma logo
$1.45 0.00 (0.00%)
As of 05/2/2025
Compare

Recent Innate Pharma SEC Filings

Export to Excel
DateFilerForm TypeView
04/30/2025
10:31 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2025
8:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
04/29/2025
5:48 PM		Innate Pharma (Subject)
Innate Pharma SA (Subject)
Sanofi (Filed by)
Sanofi (Filed by)
Form SCHEDULE 13G/A
04/29/2025
2:02 PM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/28/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/24/2025
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/23/2025
7:28 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
5:05 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/16/2025
5:07 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/03/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2025
6:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/26/2025
6:07 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/25/2025
6:23 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/20/2025
6:24 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/27/2025
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/18/2025
5:16 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/27/2025
6:57 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/21/2025
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/16/2025
7:16 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/10/2025
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/20/2024
6:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/09/2024
5:04 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/06/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/03/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/20/2024
5:02 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/19/2024
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/13/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/08/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/07/2024
5:00 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/29/2024
6:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/15/2024
5:11 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/30/2024
5:15 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/23/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2024
5:15 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2024
5:07 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/11/2024
3:00 PM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
09/09/2024
5:13 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/05/2024
5:10 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/04/2024
5:11 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/25/2024
5:06 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2024
6:43 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
Shocking AI play that’s beats Nvidia by a country mile (Ad)

You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
06/17/2024
5:02 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/04/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/28/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/24/2024
5:35 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/15/2024
5:01 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/14/2024
5:07 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/07/2024
5:03 AM		Innate Pharma (Filer)
Innate Pharma SA (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools

Related Companies
SEC Filings Tools

This page (OTCMKTS:IPHYF) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...
Stansberry Research | Sponsored
How to invest in Elon Musk’s Optimus before its launch
Elon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...
InvestorPlace | Sponsored